39 Introduction Table 2. Continued. Study Neuroimaging technique Disorder Sample size (number of females) Mean age, years (SD) Diagnosis * Medicated: unmedicated Main findings in patients (compared to controls) Patients Controls Patients Controls Gool et al. 2022 Task-based fMRI (active sleep resistance) NT1 12 (4) 12 (4) 33.3 (10.5) 32.8 (13.2) PSG, MSLT, cataplexy, HLA, CSF 5**:7 Higher left primary visual cortical activation in NT1. * Tests that were used to verify the hypersomnolence diagnosis of the included patients; ** Subjects withdrew from medication for a period prior to the start of the study. † NT1 and NT2 subjects were grouped together. CSF = Cerebrospinal fluid; EEG = Electroencephalography; FDG-PET = Fluorodeoxyglucose position emission tomography; HLA = Human leukocyte antigen; IH = Idiopathic hypersomnia; MSLT = Multi sleep latency test; NR = Not reported; NT1 = Narcolepsy type 1; NT2 = Narcolepsy type 2; PSG = Polysomnography; SOREMPs = Sleep-onset rapid eye movement periods; TSPO = 18 kDa translocator protein. 1
RkJQdWJsaXNoZXIy MjY0ODMw